|
1
|
National Comprehensive Cancer Network:
Clinical Practice Guidelines in Oncology - Ovarian Cancer version
3. 2014.http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdfAccessed.
September 01–2014
|
|
2
|
McGuire WP, Hoskins WJ, Brady MF, Kucera
PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M:
Cyclophosphamide and cisplatin compared with paclitaxel and
cisplatin in patients with stage III and stage IV ovarian cancer. N
Engl J Med. 334:1–6. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Piccart NJ, Bertelsen K, James K, Cassidy
J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, et
al: Randomized intergroup trial of cisplatin-paclitaxel versus
cisplatin-cyclophosphamide in women with advance epithelial ovarian
cancer: Three-year results. J Natl Cancer Inst. 92:699–708. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
du Bois A, Lück HJ, Meier W, Adams HP,
Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, et
al: A randomized clinical trial of cisplatin/paclitaxel versus
carboplatin/paclitaxel as first-line treatment of ovarian cancer. J
Natl Cancer Inst. 95:1320–1329. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ozols RF, Bundy BN, Greer BE, Fowler JM,
Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM
and Baergen R: Gynecologic Oncology Group: Phase III trial of
carboplatin and paclitaxel compared with cisplatin and paclitaxel
in patients with optimally resected stage III ovarian cancer: A
gynecologic oncology group study. J Clin Oncol. 21:3194–3200. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Markman M, Rothman R, Hakes T, Reichman B,
Hoskins W, Rubin S, Jones W, Almadrones L and Lewis JL Jr:
Second-line platinum therapy in patients with ovarian cancer
previously treated with cisplatin. J Clin Oncol. 9:389–393.
1991.PubMed/NCBI
|
|
7
|
Eisenhauer EA, Vermorken JB and van
Glabbeke M: Predictors of response to subsequent chemotherapy in
platinum pretreated ovarian cancer: A multivariate analysis of 704
patients [seecomments]. Ann Oncol. 8:963–968. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ferrero JM, Weber B, Geay JF, Lepille D,
Orfeuvre H, Combe M, Mayer F, Leduc B, Bourgeois H, Paraiso D and
Pujade-Lauraine E: Second-line chemotherapy with pegylated
liposomal doxorubicin and carboplatin is highly effective in
patients with advanced ovarian cancer in late relapse: A GINECO
phase II trial. Ann Oncol. 18:263–268. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sawyers C: Targeted cancer therapy.
Nature. 432:294–297. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yamamoto S, Konishi I, Mandai M, Kuroda H,
Komatsu T, Nanbu K, Sakahara H and Mori T: Expression of vascular
endothelial growth factor (VEGF) in epithelial ovarian neoplasms:
Correlation with clinicopathology and patient survival and analysis
of serum VEGF levels. Br J Cancer. 76:1221–1227. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cooper BC, Ritchie JM, Broghammer CL,
Coffin J, Sorosky JI, Buller RE, Hendrix MJ and Sood AK:
Preoperative serum vascular endothelial growth factor levels:
Significance in ovarian cancer. Clin Cancer Res. 8:3193–3197.
2002.PubMed/NCBI
|
|
13
|
Hefler LA, Zeillinger R, Grimm C, Sood AK,
Cheng WF, Gadducci A, Tempfer CB and Reinthaller A: Preoperative
serum vascular endothelial growth factor as a prognostic parameter
in ovarian cancer. Gynecol Oncol. 103:512–517. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gerber HP and Ferrara N: Pharmacology and
pharmacodynamics of bevacizumab as monotherapy or in combination
with cytotoxic therapy in preclinical studies. Cancer Res.
65:671–680. 2005.PubMed/NCBI
|
|
15
|
Smolle E, Taucher V and Haybaeck J:
Malignant ascites in ovarian cancer and the role of targeted
therapeutics. Anticancer Res. 34:1553–1561. 2014.PubMed/NCBI
|
|
16
|
Burger RA, Sill MW, Monk BJ, Greer BE and
Sorosky JI: Phase II trial of bevacizumab in persistent or
recurrent epithelial ovarian cancer or primary peritoneal cancer: A
gynecologic oncology group study. J Clin Oncol. 25:5165–5171. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cannistra SA, Matulonis UA, Penson RT,
Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D,
Wenham R and McGuire W: Phase II study of bevacizumab in patients
with platinum-resistant ovarian cancer or peritoneal serous cancer.
J Clin Oncol. 25:5180–5186. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Garcia AA, Hirte H, Fleming G, Yang D,
Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D,
et al: Phase II clinical trial of bevacizumab and low-dose
metronomic oral cyclophosphamide in recurrent ovarian cancer: A
trial of the California, Chicago and princess Margaret hospital
phase II consortia. J Clin Oncol. 26:76–82. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nimeiri HS, Oza AM, Morgan RJ, Friberg G,
Kasza K, Faoro L, Salgia R, Stadler WM, Vokes EE and Fleming GF:
Chicago Phase II Consortium; PMH Phase II Consortium; California
Phase II Consortium: Efficacy and safety of bevacizumab plus
erlotinib for patients with recurrent ovarian, primary peritoneal
and fallopian tube cancer: A trial of the Chicago, PMH and
California phase II consortia. Gynecol Oncol. 110:49–55. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McGonigle KF, Muntz HG, Viky J, Paley PJ,
Veljovich DS, Greer BE, Goff BA, Gray HJ and Malpass TW: Combined
weekly topotecan and biweekly bevacizumab in women with
platinum-resistant ovarian, peritoneal, or fallopian tube cancer:
Results of a phase 2 Study. Cancer. 117:3731–3740. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Aghajanian C, Blanck SV, Goff BA, Judson
PL, Teneriello MG, Husain A, Sovak MA, Yi J and Nycum LR: OCEANS: A
randomized, double-blind, placebo-controlled phase III trial of
chemotherapy with or without bevacizumab in patients with
platinum-sensitive recurrent epithelial ovarian, primary
peritoneal, or fallopian tube cancer. J Clin Oncol. 30:2039–2045.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pujade-Lauraine E, Hilpert F, Weber B,
Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P,
Bamias A, et al: Bevacizumab combined with chemotherapy for
platinum-resistant recurrent ovarian cancer: The AURELIA open-label
randomized phase III trial. J Clin Oncol. 32:1302–1308. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cohn DE, Valmadre S, Resnick KE, Eaton LA,
Copeland LJ and Fowler JM: Bevacizumab and weekly taxane
chemotherapy demonstrates activity in refractory ovarian cancer.
Gynecol Oncol. 102:134–139. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Monk BJ, Han E, Josephs-Cowan CA, Pugmire
G and Burger RA: Salvage bevacizumab (rhuMAB VEGF)-based therapy
after multiple prior cytotoxic regimens in advanced refractory
epithelial ovarian cancer. Gynecol Oncol. 102:140–144. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wright JD, Hagemann A, Rader JS, Viviano
D, Gibb RK, Norris L, Mutch DG and Powell MA: Bevacizumab
combination therapy in recurrent, platinum-refractory, epithelial
ovarian carcinoma: A retrospective analysis. Cancer. 107:83–89.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Richardson DL, Backes FJ, Seamon LG,
Zanagnolo V, O'Malley DM, Cohn DE, Fowler JM and Copeland LJ:
Combination gemcitabine, platinum and bevacizumab for the treatment
of recurrent ovarian cancer. Gynecol Oncol. 111:461–466. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wright JD, Secord AA, Numnum TM, Rocconi
RP, Powell MA, Berchuck A, Alvarez RD, Gibb RK, Trinkaus K, Rader
JS and Mutch DG: A multi-institutional evaluation of factors
predictive of toxicity and efficacy of bevacizumab for recurrent
ovarian cancer. Int J Gynecol Cancer. 18:400–406. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hurt JD, Richardson DL, Seamon LG, Fowler
JF, Copeland LJ, Cohn DE, Eisenhauer E, Salani R and O'Malley DM:
Sustained progression-free survival with weekly paclitaxel and
bevacizumab in recurrent ovarian cancer. Gynecol Oncol.
115:396–400. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Peitzner K, Richter R, Chekerov R, Erol E,
Oskay-Özcelik G, Lichtenegger W and Sehouli J: Bevacizumab in
heavily pre-treated and platinum resistant ovarian cancer: A
retrospective study of the North-Eastern German society of
gynaecologic oncology (NOGGO) ovarian cancer study group.
Anticancer Res. 31:2679–2682. 2011.PubMed/NCBI
|
|
30
|
Asmane I, Kurtz JE, Bajard A, Guastalla
JP, Meeus P, Tredan O, Galy Labidi I, Moullet I, Ardisson P,
Vincent L, et al: Bevacizumab plus microtubule targeting agents in
heavily pre-treated ovarian cancer patients: A retrospective study.
Bull Cancer. 98:80–89. 2011.PubMed/NCBI
|
|
31
|
National Cancer Institute: Common
Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdfAccessed.
September 01–2014
|
|
32
|
Rustin GJ, Quinn M, Thigpen T, du Bois A,
Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K,
Vergote I, et al: Re: New guidelines to evaluate the response to
treatment in solid tumors (ovarian cancer). J Natl Cancer Inst.
96:487–488. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schag CC, Heinrich RL and Ganz PA:
Karnofsky performance status revisited: Reliability, validity, and
guidelines. J Clin Oncol. 2:187–193. 1984.PubMed/NCBI
|
|
35
|
Zhu X, Wu S, Dahut WL and Parikh CR: Risks
of proteinuria and hypertension with bevacizumab, an antibody
against vascular endothelial growth factor: Systematic review and
meta-analysis. Am J Kidney Dis. 49:186–193. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hapani S, Chu D and Wu S: Risk of
gastrointestinal perforation in patients with cancer treated with
bevacizumab: A meta-analysis. Lancet Oncol. 10:559–568. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ranpura V, Hapani S and Wu S:
Treatment-related mortality with bevacizumab in cancer patients: A
meta-analysis. JAMA. 305:487–494. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
de Jesus-Gonzalez N, Robinson E, Moslehi J
and Humphreys BD: Management of antiangiogenic therapy-induced
hypertension. Hypertension. 60:607–615. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Burger RA, Brady MF, Bookman MA, Fleming
GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE,
et al: Incorporation of bevacizumab in the primary treatment of
ovarian cancer. N Engl J Med. 365:2473–2483. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ranpura V, Pulipati B, Chu D, Zhu X and Wu
S: Increased risk of high-grade hypertension with bevacizumab in
cancer patients: A meta-analysis. Am J Hypertens. 23:460–468. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Randall LM and Monk BJ: Bevacizumab
toxicities and their management in ovarian cancer. Gynecol Oncol.
117:497–504. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Qi WX, Shen Z, Tang LN and Yao Y:
Bevacizumab increases the risk of gastrointestinal perforation in
cancer patients: A meta-analysis with a focus on different
subgroups. Eur J Clin Pharmacol. 70:893–906. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pujade-Lauraine E, Hilpert F and Weber B:
AURELIA: A randomized phase III trial evaluating bevacizumab (BEV)
plus chemotherapy (CT) for platinum (PT)-resistant recurrent
ovarian cancer (OC). J Clin Oncol. 30:(suppl; abstr LBA5002).
2012.PubMed/NCBI
|
|
44
|
Wright JD, Secord AA, Numnum TM, Rocconi
RP, Powell MA, Berchuck A, Alvarez RD, Gibb RK, Trinkaus K, Rader
JS and Mutch DG: A multi-institutional evaluation of factors
predictive of toxicity and efficacy of bevacizumab for recurrent
ovarian cancer. Int J Gynecol Cancer. 18:400–406. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Randall LM and Monk BJ: Bevacizumab
toxicities and their management in ovarian cancer. Gynecol Oncol.
117:497–504. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tanyi JL, McCann G, Hagemann AR, Coukos G,
Rubin SC, Liao JB and Chu CS: Clinical predictors of
bevacizumab-associated gastrointestinal perforation. Gynecol Oncol.
120:464–469. 2011. View Article : Google Scholar : PubMed/NCBI
|
